Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (961)	5/11/1998 10:13:00 PM
From: PK	Read Replies (1) \| Respond to of 2135

Thanks for the post For the benifit of those who were too lazy to read all the way through here's the summary In the Laboratory Scientists at EntreMed Inc. near Rockville are working on five potential new medical treatments: Thalidomide This is an old drug that caused birth defects when given to pregnant women as a sedative in the late 1950s and early 1960s. But EntreMed is researching whether the drug can starve tumors by blocking formation of new blood vessels. The drug has entered human testing and EntreMed has reported positive initial results. EntreMed is also testing thalidomide's ability to prevent a leading cause of blindness. Endostatin This is a naturally occuring protein discovered in the lab of Judah Folkman, a Harvard researcher. Results in mice suggest it may help to starve tumors by blocking blood-vessel formation. Human tests have not begun. Angiostatin This is another protein discovered in Folkman's lab. Results in mice suggest it may work best in combination with Endostatin but, again, human tests have not begun. It was preliminary results in mice using this combination that led to last week's media frenzy and to speculation in EntreMed stock. EntreMed has struck a deal with Bristol-Myers Squibb Co. to develop Angiostatin. 2-ME2 2-Methoxyestradiol, also a Folkman discovery, is a compound that arises from the breakdown of estrogen in the body. It may block growth of blood vessels to tumors while at the same time directly killing cancer cells. The drug has not entered human testing. Cell permeation This intriguing technology is based on the observation that birds can fly enormous distances without tiring because their blood is better at delivering oxygen to tissues. EntreMed has developed a way to add a chemical that birds have, inositol hexaphosphate, to human blood cells. Human testing has not begun, but the hope is the treatment will prove useful in diseases like diabetes or heart trouble where tissues are starved for oxygen.